International Conference and Exhibition on Pharmaceutical Development and Technology April 24-26, 2017 Dubai, UAE

Biography:

Imran Ali, PhD, FRSC, CChem, is a world recognized Academician and Researcher. He completed his PhD from Indian Institute of Technology Roorkee, Roorkee, India. He is known globally for his great contributions in the development of chiral and anti-cancer drugs and water treatment. He has published more than 350 papers in reputed journals including papers in Nature and Chemical Reviews of more than 41 impact factor. He has also five books published by Marcel Dekker, Inc., USA; Taylor & Francis, USA; John Wiley & Sons, USA; John Wiley & Sons, UK; Elsevier, The Netherlands. His citation is 11,000 with H index 44.

Abstract:

In spite of US FDA and European agencies guidelines for marketing of optically active (homochiral) drugs, the racemic mixtures of chiral drugs are being sold and prescribed by clinicians in most of the Asian and African countries, resulting into some diseases and various side effects in human beings. It is a matter of great concern for all of us to have well developed, prosperous and healthy world. Therefore, there is a great need to design and develop economic, effective and selective methods of chiral drugs. The optically active drugs may be manufactured either by synthesis or separation of racemic mixture into optically active chiral drugs. To the best of my experience, the later approach is suitable and practical, which can be performed easily by HPLC. In this context, the development of HPLC methods for chiral separation at analytical level is the first step followed by the transfer of the developed conditions to preparative HPLC scale. The lecture will emphasize the need of chiral dugs. Besides, the state-of-art of chiral drugs development by HPLC will also be discussed. Additionally, attempts will be made to describe the modes of awareness among clinicians and general public for the need and use of chiral drugs.

Biography:

David Pugh is a chemical engineer who graduated from the Chemical engineering department of Aston University in Birmingham, UK. He has been involved in Gas, liquid, Surface Area and Particle size analysis for more than 30 years. Currently his main expertise is in the particle size analysis and zeta potential measurement of suspensions, dispersions and dry analysis of numerous commercial products especially in the pharmaceutical and Biotech sectors. His work in bringing particle size characterization out of the laboratory and into the production process via measurement on line in the granulation and micronisation processes will improve pharmaceutical product quality and understanding of the process with the added advantage of  reducing waste.

Abstract:

Dynamic Light Scattering (DLS) is a tool for determining particle size distributions in fine particulate material suspensions, micro-emulsions and nano-scale matter in general. Usually optical arrangements in lower angles are used that demand heavy dilution of samples. Backscattering, however, allows for considerably higher concentrations and is the right choice for concentrated samples which incur in processes. Furthermore, the 180° backscattering is especially suitable for direct in-line use in reactors, because the handling of the measurement probe head with a diameter of 8 mm is just as easy as a pH head. A probe sheath effectively shields the Brownian motion from the process fluidics. At higher concentrations, where particle-particle interactions are present, on-line systems with automated dilution can be used but with dilution comes the potential aggregation problems due to Chemistry. By not needing dilution in all cases DLS has finally arrived as an automatized tool for process analytics in the nanometer range of Pharmaceutics and Biotech.

Biography:

Isaac Karimi is an Academic Member in the Razi University, Iran, which he joined in 2008. He received his Doctor of Veterinary Medicine (DVM; 1998-2004) from Shahr-e-Kord University, Iran, and his Doctorate of Veterinary Sciences (PhD; 2004-2008) in Physiology from Urmia University, Iran. At Razi University, he established Enzymology Laboratory, Laboratory of Molecular and Cellular Biology 1214, and Behavioral Neuroscience Laboratory. He has an interdisciplinary view; however he is concentrated on Ethnopharmacology, Translational Research, Safety Pharmacology and Nanotoxicology. Recently, he established the research team in Computational Biology and Biomathematics. He supervised many theses and industrial R&D projects. He is Research Founder of Pars Ghousht Negin Company that produces and distributes protein products in Middle East. He received four distinguished researcher's awards from Razi University. He (co-)authored over 60 research papers and book chapters and served as a Senior Editor or an Editorial Board Member of 10 peer-reviewed journals and as a Reviewer of more than 20 peer-reviewed journals in the area of Pharmaceutics, Pharmacology, Pharmacognosy, and Biomedicines.

Abstract:

All components and properties found in the greater world, the Universe, will be searched and found in the lesser world, human (AbūḤāmidMuḥammad ibn Muḥammad al-GhazālÄ« (Algazelus), a Muslim Philosopher (c. 1058 – 1111)). More than two centuries ago, a German pharmacist Friedrich Wilhelm Adam Serturmer isolated morphine from Opium poppy (Papaver somniferum L.). Afterwards morphine congeners introduced into the market. After a long pause, by the 1973, opioid receptors and endogenous opioids (endorphins) have been discovered by researchers at Johns Hopkins University. In a similar scenario, in 1964, a Bulgarian-descent Israeli Organic Chemist, Raphael Mechoulam, identified and synthetized Δ⁹-tetrahydrocannabinol, the main psychoactive principle of hashish prepared from Cannabis sativa L. and his research team also discovered the endogenous cannabinoids, anandamide and 2-arachidonoyl glycerol (2-AG) under his supervision. Finally in 1990s, researchers in St. Louis University School of Medicine discovered cannabinoid receptors. After discovery of these two endogenous systems, we found that these systems are involving in many physiological functions besides their psychopharmacological activities. I hypothesize here, the story of opium and hashish can be repeated more quickly for other psychotropic herbs, because we are armed to cheminformatics nowadays. In this oration, I will describe a molecular dynamic methodology that generates a list of high-binding small molecule ligands found in psychoactive herbs like Passiflora incarnate, Turnera diffusa var. aphrodisiaca, Eschscholzia californica, Lobelia inflate, Aquilegia Canadensis, Juniperus virginiana, etc for selected orphan G protein-coupled receptors.

Biography:

Punniyakoti V Thanikachalam obtained his PhD from Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan. He is a Recipient of prestigious JSPS Scholarship for Postdoctoral studies in Osaka University, Japan. He has published more than 50 papers in ISI journals with cumulative impact factor of 165. His particular area of interest in research is to discover novel molecules for the treatment of cardiovascular diseases. At present, he is associated with International Medical University, Kuala Lumpur, Malaysia. 

Abstract:

Background: High levels of cortisol in humans cause metabolic abnormalities such as insulin resistance, dyslipidaemia etc., which may lead to diabetic cardiomyopathy (DCM) in type 2 diabetes mellitus (T2DM). 11beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an enzyme which is responsible for conversion  of cortisone to cortisol. Therefore, selective inhibition of 11β-HSD1 activity could offer a new approach to treat complications of T2DM.

Objective: To evaluate the efficacy of selective 11β-HSD1 inhibitor (TR-013A) in attenuating DCM in type 2 diabetic mice.

Methodology: DCM was elicited in C57BL/6J mice by feeding them with high fat diet (HFD) and intraperitoneal injection of streptozotocin at a dose of 75 mg/kg body weight once a day for three days. Mice received only chow diet served as normal control (Group I). The diabetic mice were randomly divided into three groups. Diabetic control (Group II) received vehicle (1% CMC p.o.); treatment (Group III) received TR-013A (30 mg/kg bid, p.o) and standard (Groupd IV) receieved (RU38486 10 mg/kg bid, p.o) for 21 days. Blood glucose was monitored at specific time interval during the study period.

Result & Discussion: TR-013A has significantly lowered plasma glucose level, lipid parameters compared to the diabetic control group. The plasma glucose lowering effect was comparable to that of RU38486. Furthermore, cardiac remodeling events such as inflammation, fibrosis, hypertrophy and oxidative stress were reversed by both TR-013A and RU38486 in comparison to diabetic control. Interestingly, the mice did not gain weight upon treatment with TR-013A.

Conclusion: These results demonstrate that TR-013A does exhibit anti-hyperglycaemic, anti-lipidaemic, anti-hypertrophic, anti-oxidative, anti-inflammatory and anti-fibrotic activities. Thus, inhibition of 11β-HSD1 can be an attractive therapeutic target for DCM.